Related Experiment Video
Updated: May 10, 2026
09:04
A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
Published on: March 15, 2016
Vascular endothelial growth factor gene polymorphisms and intracranial aneurysms
Marco Fontanella1, Salvatore Gallone, Pier Paolo Panciani
1Department of Neuroscience, Division of Neurosurgery, University of Turin, Turin, Italy.
Acta Neurochirurgica
|June 4, 2013
Summary
Genetic variations in the vascular endothelial growth factor (VEGF) gene were investigated for their role in aneurysmal subarachnoid hemorrhage (SAH). The study found no significant association between VEGF gene polymorphisms and SAH risk or clinical features.
Area of Science:
- Genetics
- Vascular Biology
- Neurology
Background:
- The pathophysiology of saccular aneurysms and their rupture remains unclear, with inflammation and abnormal angiogenesis implicated.
- Increased expression of angiogenesis factors, such as vascular endothelial growth factor (VEGF), is observed in aneurysm patients.
- Investigating genetic factors like VEGF polymorphisms may elucidate aneurysm development and rupture mechanisms.
Purpose of the Study:
- To determine the association of two functional polymorphisms in the vascular endothelial growth factor (VEGF) gene (+ 396 C>T and 18 bp microdeletion) with aneurysmal subarachnoid hemorrhage (SAH) susceptibility.
- To assess if these VEGF gene polymorphisms influence the clinical features of patients with aneurysmal subarachnoid hemorrhage.
- To evaluate the role of VEGF as a potential genetic risk factor for SAH in an Italian population.
Main Methods:
- Case-control study involving 200 patients with aneurysmal subarachnoid hemorrhage and 200 healthy controls.
- Determination of allelic and genotypic frequencies for the VEGF + 396 C>T polymorphism.
- Determination of allelic and genotypic frequencies for the VEGF 18 bp microdeletion polymorphism.
Main Results:
- No significant differences were found in the allelic or genotypic frequencies of the studied VEGF polymorphisms between SAH patients and controls.
- The investigated VEGF gene polymorphisms did not appear to significantly modify the primary clinical characteristics of aneurysmal subarachnoid hemorrhage.
- These findings indicate a lack of strong genetic association between the examined VEGF variants and SAH.
Conclusions:
- The vascular endothelial growth factor (VEGF) gene, specifically the studied polymorphisms, does not appear to be a major genetic risk factor for aneurysmal subarachnoid hemorrhage.
- Further research may be needed to explore other genetic or environmental factors contributing to SAH.
- These results contribute to understanding the complex etiology of aneurysmal subarachnoid hemorrhage.
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:21Aneurysm II: Clinical Manifestations and Diagnostic Studies
Thoracic, aortic arch and abdominal aneurysms are significant vascular conditions that can present with various clinical manifestations and lead to serious complications. Understanding these manifestations and the appropriate diagnostic studies is essential for effective management and treatment.Thoracic Aortic AneurysmsThoracic aortic aneurysms often remain asymptomatic until they reach a size that impinges on adjacent structures. They typically cause deep, diffuse chest pain that radiates to...